• +1-646-491-9876
    • +91-20-67278686

    Search

    Vaginal Atrophy-Pipeline Review H1 2017

    Vaginal Atrophy-Pipeline Review H1 2017

    • Report Code ID: RW0001834408
    • Category Pharmaceuticals
    • No. of Pages 42
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2017, provides an overview of the Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline landscape.

    Vaginal atrophy is thinning, drying and inflammation of the vaginal walls due to body having less estrogen. Signs and symptoms include vaginal dryness, vaginal discharge, genital itching, burning with urination, and urgency with urination, urinary tract infections and urinary incontinence. Risk factor includes smoking. Smoking impairs blood circulation, depriving the vagina and other tissues of oxygen. Tissue thinning occurs where blood flow is decreased or restricted. Treatment includes topical (vaginal) estrogen and systemic estrogen therapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Vaginal Atrophy (Atrophic Vaginitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 2 and 2 respectively.

    Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) .
    - The pipeline guide reviews pipeline therapeutics for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Vaginal Atrophy (Atrophic Vaginitis) - Overview
    Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Vaginal Atrophy (Atrophic Vaginitis) - Companies Involved in Therapeutics Development
    Allergan Plc
    Foamix Pharmaceuticals Ltd
    Mithra Pharmaceuticals SA
    PEPTONIC medical AB
    Sermonix Pharmaceuticals LLC
    TherapeuticsMD Inc
    Vaginal Atrophy (Atrophic Vaginitis) - Drug Profiles
    (estradiol + progesterone) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Estetrol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    estradiol hemihydrate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lasofoxifene tartrate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    oxytocin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    WC-3011 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects
    Vaginal Atrophy (Atrophic Vaginitis) - Product Development Milestones
    Featured News & Press Releases
    Mar 01, 2017: Acerus Files a New Drug Submission for GYNOFLOR in Canada
    May 03, 2016: Sermonix Pharmaceuticals Announces Dr. Anthony H. Wild as Board Chairman and Investor
    Mar 24, 2016: Peptonic Medical receives approval for its clinical Phase 2b study
    Feb 10, 2016: Sermonix Pharmaceuticals to Give Two Lasofoxifene Presentations at International Society for the Study of Women's Sexual Health Meeting
    Oct 07, 2015: Sermonix Receives Two Awards at the North American Menopause Society Annual Meeting
    Jul 17, 2015: Last subject exits Peptonic Medical's phase 2b VVA study
    Mar 23, 2015: Peptonic Medical's formulation patent to be approved in the USA
    Mar 18, 2015: Patient recruitment to Peptonic Medical's phase 2b study soon completed
    Feb 06, 2015: Peptonic Medical and Swetox enter collaboration on oxytocin
    Dec 01, 2014: Peptonic Medical's formulation patent to be approved in Europe
    Oct 28, 2014: First patients included in Peptonic Medical AB's clinical phase 2b study
    Sep 08, 2014: PEPTONIC Medical gets approvals to start the next clinical study
    Jul 04, 2014: PEPTONIC Medical Progress Towards Next Clinical Study
    Mar 01, 2013: Peptonic Medical Receives New Formulation Patent For Vagitocin In Sweden
    Jan 05, 2012: Peptonic's Oxytocin Receives Approval For Dose-Finding Trial From Swedish Medical Products Agency
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Allergan Plc, H1 2017
    Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Foamix Pharmaceuticals Ltd, H1 2017
    Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Mithra Pharmaceuticals SA, H1 2017
    Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by PEPTONIC medical AB, H1 2017
    Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Sermonix Pharmaceuticals LLC, H1 2017
    Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by TherapeuticsMD Inc, H1 2017
    Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Allergan Plc
    Foamix Pharmaceuticals Ltd
    Mithra Pharmaceuticals SA
    PEPTONIC medical AB
    Sermonix Pharmaceuticals LLC
    TherapeuticsMD Inc

    Request for Sample

    Report Url http://www.reportsweb.com//vaginal-atrophy-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//vaginal-atrophy-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//vaginal-atrophy-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments